Haase et al., Nephrol Dial Transplant. 20182018-09-08T14:47:35+00:00

Project Description

PHD Inhibitors in Renal Anemia

2018 Apr 16. doi: 10.1093/ndt/gfy055. [Epub ahead of print]

Effects of Vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis stimulating agents.

Haase VH, Chertow GM, Block GA, Pergola PE, deGoma E, Khawaja Z, Sharma A, Maroni BJ, McCullough PA.

Abstract

Background: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease.

Methods: In this open-label Phase 2 trial, vadadustat was evaluated in 94 subjects receiving hemodialysis, previously maintained on epoetin alfa. Subjects were sequentially assigned to one of three vadadustat dose cohorts by starting dose: 300 mg once daily (QD), 450 mg QD or 450 mg thrice weekly (TIW). The primary endpoint was mean hemoglobin (Hb) change from pre-baseline average to midtrial (Weeks 7-8) and end-of-trial (Weeks 15-16) and was analyzed using available data (no imputation).

Results: Overall, 80, 73 and 68% of subjects in the 300 mg QD, 450 mg QD, and 450 mg TIW dose cohorts respectively, completed the study. For all dose cohorts no statistically significant mean change in Hb from pre-baseline average was observed, and mean Hb concentrations-analyzed  using available data-remained stable at mid- and end-of-trial. There was one subject with an Hb excursion >13 g/dL. Overall, 83% of subjects experienced an adverse event (AE); the proportion of subjects who experienced at least one AE was similar among the three dose cohorts. The most frequently reported AEs were nausea (11.7%), diarrhea (10.6%) and vomiting (9.6%). No deaths occurred during the study. No serious AEs were attributed to vadadustat.

Conclusions: Vadadustat maintained mean Hb concentrations in subjects on hemodialysis previously receiving epoetin. These data support further investigation of vadadustat to assess its long-term safety and efficacy in subjects on hemodialysis.

read more about HIF prolyl-hydroxylase inhibitors in clinical trials

click here for link to erythropoiesis, iron metabolism and renal anemia

click here for teaching on renal anemia